A study of Moderna Inc.’s coronavirus vaccine issued in the New England Journal of Medicine reported the candidate has the potential to produce durable immunity to the virus.
In the Phase 1 trial, led by the National Institute of Allergy and Infectious Diseases (NIAID), participants across all age groups retained high levels of neutralizing antibodies through 119 days after the first vaccination, Moderna said.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
